Key highlights
- 1The Latin America clinical trial services market is expected to reach USD 8 billion by 2036, at a CAGR of 7.9% from 2026 to 2036, driven by the globalization of research and regulatory reform.
- 2Three countries dominate. Brazil (about 45.8%), Argentina (about 18.6%) and Mexico (about 13.0%) accounted for over 75% of Latin American oncology trial sites, and the three hold over two-thirds of regional trial volume.
- 3Research activity is rising. Oncology clinical trial registrations in Latin America increased by about 122% between 2010 and 2020, driven mostly by external sponsors.
- 4Brazil is reforming its framework. Brazil's Clinical Research Law 14,874/2024 and its implementing Decree 12,651/2025, published in October 2025, replaced the old ethics system and introduced time limits, including a 30-business-day cap on ethics review.
- 5Approvals are being streamlined. ANVISA's 2025 measures to reduce backlogs include a dedicated queue and reliance on international regulatory data for clinical trials, valid through 2026.
- 6CROs are investing. Global CROs including ICON, which operates across seven Latin American countries, IQVIA, Parexel and Fortrea serve the region, and PSI CRO opened a Mexico City office in 2026.
- 7Key companies include IQVIA, ICON, Parexel, Fortrea, and Thermo Fisher Scientific (PPD).
Report Overview
The Latin America clinical trial services market covers clinical research services across the region, spanning full-service trial management and monitoring, site management and patient recruitment, regulatory and safety, data management and biostatistics, and laboratory services, for Brazil, Mexico, Argentina, Colombia, Chile, Peru and the rest of Latin America. Non-clinical research and services outside the region are outside the scope except as context. Clinical trial services are the services that plan, run and support clinical trials, provided mainly by contract research organizations. Demand is shaped by the globalization of research, patient populations and recruitment, regulatory reform, and CRO investment. This report examines the size, drivers, phases, therapeutic areas, services, country markets, pricing, competition, recent developments, and outlook of the market, and provides recommendations. Sizing is built bottom-up from clinical trial services by phase, therapeutic area, service and country, and reflects the Latin American market.
Market dynamics
Drivers
- 01The globalization of clinical research is a primary driver as sponsors run trials across more regions to access patients and sites, and oncology trial registrations in Latin America rose about 122% between 2010 and 2020, mostly driven by external sponsors.
- 02Patient population and recruitment advantages are a driver as the region offers large, diverse and, in many areas, treatment-naive populations, and industry sources report faster enrollment and higher retention, and costs that can be lower than in the United States or Europe, though these advantages are often vendor claims rather than independently verified.
- 03Regulatory reform is a driver as Brazil's Clinical Research Law 14,874/2024 and its 2025 implementing decree, and ANVISA's measures to reduce approval backlogs including reliance on international regulatory data, aim to make approvals faster and more predictable.
- 04CRO presence and investment are a driver as global and local CROs expand in the region.
Opportunities
- 01Brazil as an emerging hub is a leading opportunity as its regulatory reform aims to improve predictability and attract more global trials to the region's largest market.
- 02Oncology and specialty trials are an opportunity as oncology is the leading and fast-growing area and the region is underrepresented relative to its cancer burden.
- 03Decentralized and hybrid trials are an opportunity as digital and decentralized approaches can extend trials to more patients and sites.
- 04Expansion beyond the leading countries is an opportunity as Colombia, Chile, Peru and others grow their share, with new trial sites not concentrated in a single country.
Trends
- 01Regulatory modernization is a defining trend as Brazil's new law and decree and ANVISA's reforms modernize the framework, with other countries also streamlining.
- 02Oncology concentration is a trend as oncology dominates trial activity and growth.
- 03A mixed global and local CRO ecosystem is a trend as global CROs such as ICON, IQVIA, Parexel and Fortrea operate alongside regional and local CROs.
- 04Dispersion beyond the big three is a trend as growth in new sites spreads to smaller countries.
Report Summary
| Base Year | 2025 |
|---|---|
| Forecast Period | 2026-2036 |
| Market Size (2025) | USD 3.5 billion |
| Market Size (2026) | USD 3.8 billion |
| Market Size (2036) | USD 8 billion |
| CAGR (Value) | 7.9% (2026-2036) |
| Format | PDF & Excel |
| Segments Covered | By Phase: Phase I, II, III, IV. By Therapeutic Area: Oncology, Cardiovascular & Metabolic, Infectious Diseases, CNS, Others. By Service Type; By Country. |
| Geographies Covered | Brazil, Mexico, Argentina, Colombia, Chile, Peru, and Rest of Latin America |
| Key Companies | IQVIA, ICON, Parexel, Fortrea, Thermo Fisher Scientific (PPD), Syneos Health, Worldwide Clinical Trials, PSI CRO, Azidus Brasil, EvolveCRO, Other Companies |
Segmental analysis
By Phase
- Phase III holds the largest share at about 55% of the market in 2026, with Phase II at about 25% , Phase IV at about 12% , and Phase I accounting for the remainder.
- Phase III the large pivotal trials that test efficacy and safety in many patients, is by far the largest phase because Latin America's main role in global research is to contribute patients and sites to large multi-country Phase III trials, particularly in oncology.
- Phase II testing efficacy in smaller groups, is a significant phase.
- Phase IV post-marketing studies, is a substantial phase.
- Phase I early first-in-human and pharmacology studies, is a smaller phase as these are more concentrated in established research hubs.
The dominance of Phase III reflects the region's role in large multi-country trials, while earlier phases grow as capacity develops.
By Therapeutic Area
- Oncology holds the largest share at about 38% of the market in 2026, with cardiovascular and metabolic at about 18% , infectious diseases at about 16% , central nervous system at about 10% , and other areas accounting for the remainder.
- Oncology is the largest and fastest-growing area because cancer trials dominate global research and Latin America's participation in oncology has grown strongly, though it remains below the region's potential.
- Cardiovascular and metabolic trials including diabetes, are large given the region's disease burden.
- Infectious diseases including vaccines, are significant, as the region played a major role in COVID-19 and other vaccine trials.
- Central nervous system and other areas complete the market.
The dominance of oncology reflects global research priorities and the region's growing oncology base, while cardiometabolic and infectious diseases reflect the regional disease burden.
By Service Type
- Trial management and monitoring hold the largest share at about 45% of the market in 2026, with site management and patient recruitment at about 22% , regulatory and safety at about 13% , data management and biostatistics at about 12% , and laboratory services accounting for the remainder.
- Trial management and monitoring the core of running a trial, are the largest service as full-service CROs manage trials end to end.
- Site management and patient recruitment are a large service central to the region's value of access to patients.
- Regulatory and safety services navigate the region's evolving approvals.
- Data management and biostatistics and laboratory and bioanalytical services, complete the offering.
The dominance of trial management reflects full-service delivery, while recruitment reflects the region's patient-access value.
Geographic analysis
Brazil Clinical Trial Services Market
Brazil is by far the largest market accounting for about 45.8% of Latin American oncology trial sites and the highest participation in clinical research in the region, though still below its potential. Brazil is modernizing its framework through Clinical Research Law 14,874/2024 and its implementing Decree 12,651/2025, published in October 2025, which replaced the former CEP/CONEP ethics system with a National System of Ethics in Research, moved oversight to a Ministry of Health science and innovation secretariat, and set time limits including a 30-business-day cap on ethics review, while ANVISA introduced measures to reduce backlogs and rely on international regulatory data. These reforms aim to make Brazil a regional hub, though their benefits are not yet measured and the law faces a constitutionality challenge. Brazil's scale, research base and reforms make it the leading market.
Mexico Clinical Trial Services Market
Mexico is the second-largest market with about 13.0% of regional oncology sites and a large population, and is described by CROs as Latin America's second-largest clinical trial market. Mexico offers relatively faster regulatory timelines, with approvals reported at around 2.8 months, through COFEPRIS, and proximity to the United States, and CROs such as PSI have expanded there, opening a Mexico City office in 2026. Mexico's population, timelines and proximity to the United States make it a leading and growing market.
Argentina and Andean Countries Clinical Trial Services Market
Argentina is a major market with about 18.6% of regional oncology sites and a strong research tradition and medical infrastructure, though regulatory timelines through ANMAT are longer, reported at around 4.5 months, and economic and currency instability is a challenge. Colombia, Chile and Peru are growing markets with developing research capacity and are capturing a growing share as activity disperses beyond the big three. These countries combine research capacity with growth, with Argentina a major base despite macroeconomic volatility. Argentina and the Andean countries are significant and growing markets, with Argentina large but challenged by instability.
Rest of Latin America Clinical Trial Services Market
The rest of Latin America including Central America, Guatemala, where ICON operates, and other countries, is an emerging market capturing a growing share as new trial sites spread beyond the largest countries. These markets add growing capacity and demand as the region's research footprint expands. The rest of Latin America is an emerging and growing part of the market as research disperses across the region.
Pricing Analysis
Pricing in clinical trial services in Latin America reflects the cost advantage relative to the United States and Europe, the complexity and phase of the trial, and regional logistics. Industry sources report that running trials in Latin America can cost less than in the United States or Europe, with some claiming up to 30% lower costs, driven by lower site and labor costs and faster recruitment, though these figures are vendor claims and not independently verified, and the net advantage depends on logistics and complexity. Several factors set cost. Site, investigator and labor costs are lower than in higher-cost regions, supporting the cost advantage. Patient recruitment and retention, reported to be faster and higher in the region, can lower per-patient and overall cost. The phase and therapeutic complexity drive cost, with Phase III and oncology trials more complex. Regulatory navigation, and the import and customs handling of investigational products, add cost and time. Currency volatility, particularly in Argentina, affects cost and predictability.
The trajectory of the region's cost competitiveness depends on recruitment performance, regulatory efficiency and macroeconomic stability, and while the cost advantage is real, it is moderated by logistics, regulation and currency, so the region competes on access and cost together rather than cost alone.
Competitive landscape
The market is served by global contract research organizations and regional and local CROs. Global CROs lead, with ICON, which describes itself as the first and one of the largest CROs in the region, operating across Argentina, Brazil, Chile, Colombia, Guatemala, Mexico and Peru, and IQVIA, Parexel, Fortrea, Thermo Fisher's PPD, Syneos Health and Worldwide Clinical Trials running trials in the region across therapeutic areas. PSI CRO expanded with a Mexico City office in 2026. Regional and local CROs, including Azidus Brasil and oncology-focused EvolveCRO, and others such as Cohortias, provide local expertise and site networks.
Competition turns on local presence and site networks, therapeutic and regulatory expertise, recruitment capability, and global integration, and the market combines global CROs with regional and local players. The globalization of research and the region's patient access favour CROs with strong local networks, regulatory expertise and recruitment capability integrated into global trials, and global CROs lead while local CROs provide regional depth. The field is served by established global CROs and a growing local ecosystem, and local presence, expertise, recruitment and integration shape competition, with regulatory reform and research growth the key variables.
Voice of Customer
We include Latin America in our global Phase III programs for access to large, diverse patient populations and strong recruitment, particularly in oncology, and Brazil, Mexico and Argentina are our main countries. Brazil's regulatory reform is encouraging, as predictability has been our biggest concern, but we are watching how the new law and its post-study obligations work in practice before expanding further.
Clinical operations director, global pharmaceutical sponsor:
Demand for trials in Brazil is strong, and the new Clinical Research Law and decree aim to fix the slow ethics and regulatory process that held the country back, with a 30-day review cap and reliance on international data. The reforms are promising, but they are new and face legal challenge, so we are managing both the opportunity and the uncertainty while building site and recruitment capacity.
Country head, contract research organization (Brazil):
Our patients gain access to new therapies through trials, and the region is underrepresented relative to our cancer burden, so there is large unmet potential. The constraints are regulatory timelines, the import of investigational products, and infrastructure, and addressing these, along with the economic instability in some countries, is what will let the region realise its potential in clinical research.
Site investigator, oncology research center (Latin America):
Analyst perspective
The Latin America clinical trial services market is a steadily growing market with real structural advantages and a modernizing regulatory environment, and one where the opportunity is large but the region remains underrepresented relative to its potential. Latin America offers large, diverse patient populations, a significant disease burden in oncology and cardiometabolic disease, and, as industry sources report, strong recruitment and lower costs, and its participation in global research has grown, with oncology registrations up about 122% between 2010 and 2020. Activity is concentrated in Brazil, Mexico and Argentina, which hold over two-thirds of trial volume, and Brazil's Clinical Research Law 14,874/2024 and its 2025 decree, together with ANVISA's backlog reforms, aim to make the region's largest market a genuine hub by improving the predictability that sponsors have long cited as the main obstacle.
The honest considerations are underrepresentation, unproven reforms, concentration, and instability. Despite its advantages, the region has been underrepresented in clinical research relative to its population and disease burden, and even Brazil's participation is below its potential, so the opportunity is as much about closing a gap as riding growth. The reforms, while promising, are new and their benefits are not yet measured, and Brazil's law faces a constitutionality challenge and includes a post-study supply obligation that some analysts argue undermines sponsors' economic predictability and could discourage investment, so the regulatory improvement is real but not assured. Activity is heavily concentrated in three countries, and site capacity, infrastructure and the import of investigational products are constraints elsewhere. Macroeconomic and currency instability, particularly in Argentina, affects cost and predictability. The recruitment and cost advantages, while real, are often vendor claims rather than independently verified. The market should be assessed on the realisation of regulatory reform, the dispersion of capacity beyond the big three, recruitment performance, and macroeconomic stability rather than on the region's potential alone, and globalization, patient access, reform and CRO investment support steady growth, with underrepresentation, reform execution, concentration and instability the key variables.
Key Strategic Developments
- 2024: Brazil enacted Clinical Research Law 14,874/2024, replacing the former CEP/CONEP ethics system with a National System of Ethics in Research and setting time limits, including a 30-business-day cap on ethics review.
- October 2025: Brazil published implementing Decree 12,651/2025, establishing the governance and operational structure of the new National System of Ethics in Research involving human subjects.
- 2025: ANVISA announced measures to reduce approval backlogs, including a dedicated queue and reliance on international regulatory data for clinical trials, valid through 2026, and a mechanism for continuous submission of safety and efficacy data.
- 2026: PSI CRO opened a Mexico City office, describing Mexico as Latin America's second-largest clinical trial market and expanding capacity for pivotal and oncology trials.
- 2024-2026: Oncology trial activity continued to grow across the region, concentrated in Brazil, Argentina and Mexico, with new sites increasingly spreading to Colombia, Chile, Peru and other countries.
Strategic Recommendations
For contract research organizations and sponsors
The priority is to build local capacity and navigate the modernizing regulation while managing the region's constraints, because Latin America offers patient access and cost advantages and improving regulation but remains underrepresented and concentrated, and local capability and regulatory navigation decide success. Companies should build site networks and recruitment capacity, including beyond Brazil, Mexico and Argentina, develop regulatory expertise for Brazil's new framework and other countries, invest in oncology and specialty capability, and adopt decentralized approaches to extend reach. Monitoring the implementation and legal status of Brazil's reforms and managing logistics and currency risk strengthen the position.
For sponsors
The recommendation is to include the region in global programs for patient access and recruitment, focusing on the leading countries while piloting expansion, and to plan for regulatory and post-study obligations. For policymakers, realising regulatory reform, reducing approval times, and easing the import of investigational products build the region's competitiveness. For investors, this is a steadily growing market to evaluate on regulatory reform realisation, dispersion of capacity, recruitment performance, and macroeconomic stability rather than on the region's potential alone, recognising that globalization, patient access, reform and CRO investment support growth while underrepresentation, reform execution, concentration and instability are the key variables.
Sustainability impact
Access to Medicines and Research
Clinical trials give patients in Latin America access to new therapies and build local research capacity. This market supports health access.
By bringing trials to the region, clinical trial services give patients access to new and investigational therapies, particularly in oncology where the region is underrepresented, and build local research capacity, expertise and infrastructure, contributing to health and scientific development.
Diverse and Representative Research
Including Latin American populations makes clinical research more diverse and representative. This market supports better science.
By including the region's large and diverse populations, clinical trials become more representative of global patients, improving the generalisability of results and addressing the historical underrepresentation of the region, which benefits patients worldwide.
Economic and Scientific Development
Clinical research investment supports jobs, expertise and economic development in the region. This market supports development.
By investing in sites, staff and services, clinical research creates skilled jobs, builds scientific and medical expertise, and brings investment to the region, supporting economic and scientific development alongside the health benefits of trials.
Ethics, Equity and Post-Study Access
The benefits depend on strong ethics, equity, and post-study access to therapies for participants. This market requires ethical safeguards.
By involving human participants, clinical research must uphold strong ethics, informed consent, equity, and post-study access to beneficial therapies, as addressed in Brazil's new law, so that participants and communities share in the benefits and are protected, which is central to the sustainability and legitimacy of research.
Table of contents
14 chapters · 213 pages · click to expandFrequently asked questions
The Latin America clinical trial services market was valued at USD 3.5 billion in 2025 and is projected to reach USD 8 billion by 2036, growing from USD 3.8 billion in 2026, at a CAGR of 7.9% from 2026 to 2036, driven by the globalization of research and regulatory reform.